Skip to main content
Premium Trial:

Request an Annual Quote

Richard Wenstrup

Epic Sciences has appointed Richard Wenstrup as its chief medical officer. Wenstrup has served in several clinical leadership roles managing life science companies in the past 25 years. Before Epic, he previously served as CMO for Oxford Immunotec, where he oversaw research and development, product development, regulatory, medical, and clinical affairs. From 2006 to 2017, Wenstrup served as CMO at Myriad Genetics. Prior to Myriad, Wenstrup was a pediatrics professor in human genetics at Cincinnati Children's Hospital Medical Center and professor of biomedical engineering at the University of Cincinnati. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.